Maxadilan

Maxadilan is a specific irreversible PAC1 receptor agonist and a potent vasodilator peptide present in the salivary glands of sand flies. Maxadilan exhibits anti-apoptotic activity in hADSCs. Maxadilan inhibits pro-inflammatory cytokines (TNF-α) and enhances anti-inflammatory mediators (IL-10) . Maxadilan can activate leukocytes and inhibit vascular permeability through PAC1 receptors. Maxadilan promotes neural differentiation of human adipose-derived stem cells. Maxadilan can be used to study endotoxin shock, atherosclerosis, and neurodegenerative diseases[1][2][3][4][5].

Product Specifications

CAS Number

[135374-80-0]

UNSPSC

12352209

Target

Apoptosis; Caspase; Interleukin Related; PACAP Receptor; PKA; TNF Receptor

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease; Cardiovascular Disease

Smiles

O=C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@H]1[C@H](O)C)=O)=O)[C@H](CSSC[C@@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CCSC)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC4=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CC5=CNC=N5)C(N[C@@H](CC6=CNC=N6)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC7=CC=CC=C7)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N8[C@@H](CCC8)C(NCC(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N[C@@H](CC9=CC=CC=C9)C(N[C@@H](CCCCN)C(N[C@H]4CCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)N

Molecular Formula

C291H466N86O94S6

Molecular Weight

6865.72

References & Citations

[1]Mey L, et al. PAC1 Agonist Maxadilan Reduces Atherosclerotic Lesions in Hypercholesterolemic ApoE-Deficient Mice. Int J Mol Sci. 2024 Dec 10;25 (24) :13245.|[2]Guo X, et al.PAC1R agonist maxadilan enhances hADSC viability and neural differentiation potential. J Cell Mol Med. 2016 May;20 (5) :874-90.|[3]Svensjö E, et al.Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage via PAC1-CXCR1/2-pathway. Microvasc Res. 2012 Mar;83 (2) :185-93.|[4].Yu R, et al. Long-term administration of maxadilan improves glucose tolerance and insulin sensitivity in mice. Peptides. 2008 Aug;29 (8) :1347-53.|[5]Bozza M, S et al The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. Eur J Immunol. 1998 Oct;28 (10) :3120-7.